Pemetrexed
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Pemetrexed: From Malignant Pleural Mesothelioma to Malignant Peritoneal Mesothelioma
One-Sentence Summary
Pemetrexed is a multitargeted antifolate chemotherapy agent whose established use — in combination with cisplatin — is the treatment of malignant pleural mesothelioma and non-squamous NSCLC. The TxGNN model predicts it may also be effective for Malignant Peritoneal Mesothelioma, a rarer mesothelial-lining cancer, with 10 clinical trials and 10 curated publications currently supporting this direction — though no dedicated Phase 3 RCT exists for this specific subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Malignant Pleural Mesothelioma (in combination with cisplatin) — pemetrexed's established, guideline-recognised standard-of-care indication |
| Predicted New Indication | Malignant Peritoneal Mesothelioma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed structured mechanism-of-action data was not available in this evidence pack (DrugBank MOA field is a data gap). However, the underlying evidence base consistently describes pemetrexed as a multitargeted antifolate that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) — enzymes essential to folate-dependent DNA and RNA precursor synthesis. This cytotoxic mechanism is well validated in malignant pleural mesothelioma, where pemetrexed plus cisplatin became the standard first-line regimen following the pivotal Phase 3 trial (Vogelzang et al., 2003).
Malignant peritoneal mesothelioma and malignant pleural mesothelioma both arise from mesothelial cells — one lining the pleural cavity, the other the peritoneal cavity — and share overlapping histology, asbestos-related pathogenesis, and antifolate drug sensitivity. Because no dedicated, guideline-endorsed systemic regimen exists for the peritoneal subtype, oncologists have empirically extrapolated the pleural mesothelioma regimen (pemetrexed + cisplatin) to peritoneal disease.
This extrapolation is supported by real-world and retrospective clinical experience: Fujimoto et al. (2017) and Nagata et al. (2019) both report on first-line pemetrexed-cisplatin specifically in malignant peritoneal mesothelioma cohorts, and multiple case series (e.g., rechallenge with cisplatin-pemetrexed, Gilani et al. 2013) describe meaningful responses. This gives the TxGNN prediction plausible mechanistic and clinical-practice grounding, even though a confirmatory randomized trial specific to the peritoneal subtype is still lacking.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05001880 | Phase 2 | Recruiting | 66 | Randomized trial comparing carboplatin/pemetrexed/bevacizumab ± atezolizumab as neoadjuvant or palliative therapy for peritoneal mesothelioma |
| NCT06057935 | Phase 2 | Recruiting | 64 | Randomized comparison of intraperitoneal vs. intravenous chemotherapy after cytoreductive surgery + HIPEC in malignant peritoneal mesothelioma |
| NCT00061477 | Phase 2 | Completed | 48 | Pemetrexed plus gemcitabine as front-line therapy for pleural or peritoneal mesothelioma; assessed safety, tumor response, and survival |
| NCT06543069 | Phase 2 | Recruiting | 28 | Single-arm study of sintilimab + bevacizumab combined with pemetrexed/cisplatin in unresectable malignant peritoneal mesothelioma |
| NCT03875144 | Phase 2 | Suspended | 66 | Randomized trial of PIPAC + systemic chemotherapy (cisplatin/pemetrexed) vs. systemic chemotherapy alone as first-line treatment |
| NCT04462809 | Phase 2 | Unknown | 40 | Three-cohort trial of maintenance talazoparib after first-line platinum-based chemotherapy in pleural or peritoneal mesothelioma |
| NCT02535312 | Phase 1/2 | Active, not recruiting | 30 | Methoxyamine (TRC102) + cisplatin/pemetrexed in solid tumors/mesothelioma refractory to pemetrexed-cisplatin or -carboplatin |
| NCT00402766 | Phase 1 | Completed | 19 | Cisplatin + pemetrexed + imatinib mesylate in unresectable/metastatic malignant mesothelioma; determined maximum tolerated dose |
| NCT02029690 | Phase 1 | Terminated | 85 | ADI-PEG 20 + pemetrexed + cisplatin in arginine-dependent tumors, including an advanced peritoneal mesothelioma dose-escalation cohort |
| NCT03564691 | Phase 1 | Completed | 470 | MK-4830 monotherapy/combination with pembrolizumab in a broad advanced solid tumor basket study, including mesothelioma |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28594258 | 2017 | Retrospective study | Expert Review of Anticancer Therapy | First-line pemetrexed + cisplatin efficacy specifically evaluated in malignant peritoneal mesothelioma (MPeM) patients |
| 31287877 | 2019 | Retrospective study | Japanese Journal of Clinical Oncology | Efficacy and safety of pemetrexed + cisplatin as first-line therapy in advanced MPeM; efficacy previously unclear, now characterized |
| 41133016 | 2025 | Retrospective study | Clinical Medicine Insights: Oncology | Comparison of first-line pemetrexed-platinum vs. gemcitabine-platinum regimens in MPeM |
| 33743636 | 2021 | Retrospective study | BMC Cancer | Efficacy of second-line treatment and prognostic factors in advanced MPeM following first-line pemetrexed-based therapy |
| 38806763 | 2024 | Multi-center cohort | Annals of Surgical Oncology | Treatment strategies and outcomes across a multi-center MPeM cohort |
| 23291819 | 2013 | Case report | BMJ Case Reports | MPeM patient responding to rechallenge with cisplatin + pemetrexed, with literature review |
| 31417959 | 2019 | Cohort | Pleura and Peritoneum | Bidirectional chemotherapy (including pemetrexed-based regimens) enabling surgery + HIPEC for initially unresectable MPeM |
| 35407498 | 2022 | Review | Journal of Clinical Medicine | Comprehensive review of treatment approaches for malignant peritoneal mesothelioma |
| 26941986 | 2016 | Review | Journal of Gastrointestinal Oncology | Diagnosis and management of MPeM, including systemic chemotherapy options |
| 30450291 | 2018 | Review | Translational Lung Cancer Research | General review of malignant peritoneal mesothelioma biology and treatment |
Cytotoxicity
Pemetrexed is a conventional cytotoxic antineoplastic agent (antifolate/antimetabolite class), which triggers this section.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (antifolate/antimetabolite) |
| Myelosuppression Risk | High — neutropenia, thrombocytopenia, and anemia are well-documented, particularly when combined with platinum agents (e.g., cisplatin) |
| Emetogenicity Classification | Moderate as monotherapy; High when combined with cisplatin |
| Monitoring Items | CBC with differential before each cycle, renal function (creatinine clearance), liver function tests; folic acid and vitamin B12 supplementation is required to reduce toxicity |
| Handling Protection | Must be handled under standard cytotoxic/hazardous drug handling protocols (closed-system transfer, PPE, controlled disposal) |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Peritoneal mesothelioma shares mechanistic and histologic biology with pemetrexed's core approved indication (pleural mesothelioma), and multiple retrospective/cohort studies plus several active Phase 2 trials support pemetrexed-cisplatin activity in this subtype. However, no dedicated Phase 3 RCT has confirmed efficacy specifically in peritoneal disease, and the drug currently holds no market authorization in this jurisdiction (0 licenses, not marketed).
To proceed, the following is needed:
- Official product label warnings and contraindications (currently a blocking data gap — required before S1 safety screening can be completed)
- Structured DrugBank mechanism-of-action data to formally document the target pathway rationale
- Confirmation of local market authorization pathway, given current "not marketed" status with zero licenses
- A dedicated prospective/randomized trial (or mature real-world outcomes data) specific to malignant peritoneal mesothelioma to upgrade evidence beyond L2
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.